Bibliografia UJ CM

1/6
Jennifer R. Brown, John C. Byrd, Paolo Ghia, Jeff P. Sharman, Peter Hillmen, Deborah M. Stephens, Clare Sun, Wojciech Jurczak, John M. Pagel, Alessandra Ferrajoli, Priti Patel, Lin Tao, Nataliya Kuptsova-Clarkson, Javid Moslehi, Richard R. Furman.
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy : pooled analysis of 762 patients
Haematologica
2022 : Vol. 107, nr 6, s. 1335-1346, il., bibliogr. 52 poz., abstr.
Autor korespondencyjny: Jennifer R. Brown
Open Access Creative Commons Attribution License CC-BY-NC 4.0
p-ISSN: 0390-6078
AZ
ORG
AIF
IF: 10.100
Adres url:
Streszczenie w PubMed:
2/6
Jeff P. Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Emmanuelle Ferrant, William G. Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C. Byrd.
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia.
Leukemia
2022 : Vol. 36, nr 4, s. 1171-1175, il., bibliogr. 12 poz.
Autor korespondencyjny: Jeff P. Sharman.
Open Access Creative Commons Attribution License CC-BY 4.0.
p-ISSN: 0887-6924
e-ISSN: 1476-5551
LR
AIF
IF: 11.400
Adres url:
Streszczenie w PubMed:
3/6
Matthew S. Davids, Owen A. O'Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske, Pier Luigi Zinzani, Manish R. Patel, Nilanjan Ghosh, Bruce D. Cheson, Enrico Derenzini, Danielle M. Brander, James A. Reeves, Wanda Knopinska-Posluszny, John N. Allan, Tycel Phillips, Paolo F. Caimi, Ewa Lech-Maranda, John M. Burke, Richy Agajanian, Ruth Pettengell, Lori A. Leslie, Chan Y. Cheah, Gustavo Fonseca, James H. Essell, Julio C. Chavez, John M. Pagel, Jeff P. Sharman, Yanzhi Hsu, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Ian W. Flinn.
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε nhibitor, in relapsed/refractory lymphoid malignancies.
Blood Advances
2021 : Vol. 5, nr 23, s. 5332-5343, il., bibliogr. 50 poz., abstr.
Autor korespondencyjny: Matthew S. Davids.
p-ISSN: 2473-9529
e-ISSN: 2473-9537
AZ
ORG
AIF
IF: 7.642
Adres url:
Streszczenie w PubMed:
4/6
Richard R. Furman, John C. Byrd, Roger G. Owen, Susan M. O'Brien, Jennifer R. Brown, Peter Hillmen, Deborah M. Stephens, Nataliya Chernyukhin, Tamara Lezhava, Ahmed M. Hamdy, Raquel Izumi, Priti Patel, Marshall Baek, Beth Christian, Martin J. S. Dyer, Matthew J. Streetly, Clare Sun, Simon Rule, Michael Wang, Paolo Ghia, Wojciech Jurczak, John M. Pagel, Jeff P. Sharman.
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.
Leukemia
2021 : Vol. 35, nr 11, s. 3201-3211, il., bibliogr. 41 poz., abstr.
Autor korespondencyjny: Richard R. Furman.
p-ISSN: 0887-6924
e-ISSN: 1476-5551
AZ
ORG
AIF
IF: 12.897
Adres url:
Streszczenie w PubMed:
5/6
Nathan H. Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopinśka-Posłuszny, Chan Y. Cheah, Tycel Phillips, Ewa Lech-Maranda, Bruce D. Cheson, Paolo F. Caimi, Sebastian Grosicki, Lori A. Leslie, Julio C. Chavez, Gustavo Fonseca, Sunil Babu, Daniel J. Hodson, Spencer H. Shao, John M. Burke, Jeff P. Sharman, Jennie Y. Law, John M. Pagel, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Michael S. Weiss, Pier Luigi Zinzani.
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
Journal of Clinical Oncology
2021 : Vol. 39, nr 15, s. 1609-1618, il., bibliogr. 40 poz., abstr.
Autor korespondencyjny: Pier Luigi Zinzani.
Open Access Creative Commons Attribution License CC-BY-NC-ND 4.0.
p-ISSN: 0732-183X
AZ
ORG
AIF
IF: 50.739
Adres url:
Streszczenie w PubMed:
6/6
Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R. Brown, Bertrand Coiffier, Julio Delgado, Miklós Egyed, Paolo Ghia, Árpad Illes, Wojciech Jurczak, Paula Marlton, Marco Montillo, Franck Morschhauser, Alexander S. Pristupa, Tadeusz Robak, Jeff P. Sharman, David Simpson, Lukas Smolej, Eugen Tausch, Adeboye H. Adewoye, Lyndah K. Dreiling, Yeonhee Kim, Stephan Stilgenbauer, Peter Hillmen.
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet. Oncology
2017 : Vol. 18, nr 3, s. 297-311, il., bibliogr. 22 poz., sum.
Autor korespondencyjny: Andrew D. Zelenetz.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 36.418
Adres url:
Streszczenie w PubMed:
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ